Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1;18(9):sfaf242.
doi: 10.1093/ckj/sfaf242. eCollection 2025 Sep.

Management and treatment of chronic kidney disease in the Danish Lolland-Falster Health Study: focus on renoprotection and cardiovascular disease prevention

Ebba Mannheimer  1 , Morten Buus Jørgensen  1 , Kristine Hommel  2   3 , Anne-Lise Kamper  1 , Randi Jepsen  4 , Bo Feldt-Rasmussen  1   3 , Mads Hornum  1   3
Affiliations

Management and treatment of chronic kidney disease in the Danish Lolland-Falster Health Study: focus on renoprotection and cardiovascular disease prevention

Ebba Mannheimer et al. Clin Kidney J. .

Abstract

Background: In the Danish population-based Lolland-Falster Health Study (LOFUS), we recently identified a chronic kidney disease (CKD) prevalence of 18%. Importantly, overall disease recognition was only 7.1%, and awareness was as low as 4.4%. This reveals a significant gap in identifying CKD, consequently delaying initiation of guideline-directed renoprotective treatments, cardiovascular disease prevention, and referrals to specialized nephrology care.

Methods: Cross-sectional study including adult participants with CKD identified in LOFUS. Data were obtained from biochemical analyses, clinical examinations, and questionnaires. Redeemed prescriptions and nephrology referrals were assessed using national medical registers. Blood pressure control, treatment with renin-angiotensin-system inhibitors and statins, as well as lifestyle factors were examined, and their association with CKD stage analyzed.

Results: Among 2881 individuals with CKD, 57.6% were women, median age was 67.8 years, 71.3% were in CKD stages 1-2 and 21% had cardiovascular disease. Less than half of individuals had blood pressure control (47.5%). Treatment with renin-angiotensin-system inhibitors and statins, when indicated, were 72.8% and 32.2%, respectively, and more frequent in individuals with diabetes. In multivariable analyses, the odds ratios for blood pressure control (1.68; 95% CI,1.12-2.52), treatment with renin-angiotensin-system inhibitors (7.91; 95% CI,2.14-29.18), and statins (1.77; 95% CI,1.06-2.96) were significantly higher in stages 3b-5 compared to stage 1. Less than one-third had a BMI <25 kg/m2 and >80% self-reported non-smoking. Of those meeting nephrology referral criteria (n = 99), one-third had been referred.

Conclusion: Our findings highlight gaps between guideline-recommended CKD management and practice, particularly in early stages and in non-diabetic individuals, emphasizing the need for early detection and improved guideline adherence.

Keywords: blood pressure; cardiovascular disease; chronic kidney disease; epidemiology; renoprotection.

PubMed Disclaimer

Conflict of interest statement

M.H. reports honoraria for advisory boards for Astra Zeneca, Bayer, Boeringer Ingelheim, Vifor, GSK, and Novo Nordisk A/S and education for Astra Zeneca, Boeringer Ingelheim and Novo Nordisk A/S outside the scope of this paper. E.M. reports research grants from the Danish Kidney Association, the Danish Society of Nephrology, and Helen and Ejnar Bjørnow Foundation. The remaining authors declare no conflict of interest.

Figures

GRAPHICAL ABSTRACT
GRAPHICAL ABSTRACT
See this image and copyright information in PMC

References

    1. Sundström J, Bodegard J, Bollmann A et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: the CaReMe CKD study. Lancet Regional Health Europe 2022;20:100438. 10.1016/j.lanepe.2022.100438 - DOI - PMC - PubMed
    1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305. 10.1056/NEJMoa041031 - DOI - PubMed
    1. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–52. https://annals.org - PubMed
    1. Xie X, Liu Y, Perkovic V et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016;67:728–41. 10.1053/j.ajkd.2015.10.011 - DOI - PubMed
    1. Jepsen R, Egholm CL, Brodersen J et al. Lolland-Falster Health Study: study protocol for a household-based prospective cohort study. Scand J Public Health 2020;48:382–90. 10.1177/1403494818799613 - DOI - PMC - PubMed

LinkOut - more resources